Literature DB >> 19804472

Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1.

V Rakocevic Stojanovic1, S Peric, D Lavrnic, S Popovic, T Ille, Z Stevic, I Basta, S Apostolski.   

Abstract

OBJECTIVES: To evaluate serum leptin concentration and its relation to metabolic syndrome (MSy) in non-diabetic patients with myotonic dystrophy type 1 (DM1).
MATERIALS AND METHODS: This study included 34 DM1 patients, and the same number of healthy subjects matched for age, sex and body mass index (BMI).
RESULTS: DM1 patients had increased BMI and insulin resistance, and increased leptin and insulin concentrations, but the other features of MSy such as diabetes, glucose intolerance and hypertension were not detected in DM1 patients. Serum leptin levels were higher in patients with DM1 than in healthy controls (8.5 +/- 6.6 ng/ml vs 3.6 +/- 2.9 ng/ml in men, and 13.9 +/- 10.0 ng/ml vs 10.9 +/- 6.9 ng/ml in women, respectively). In DM1 patients, leptin levels correlated with BMI, fasting insulin and insulin resistance (HOMA) (P < 0.01).
CONCLUSIONS: The leptin overproduction correlated with insulin resistance in DM1 patients but the significance of this finding remains unclear.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804472     DOI: 10.1111/j.1600-0404.2009.01237.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

Review 1.  Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy.

Authors:  Marie-Laure Caillet-Boudin; Francisco-Jose Fernandez-Gomez; Hélène Tran; Claire-Marie Dhaenens; Luc Buee; Nicolas Sergeant
Journal:  Front Mol Neurosci       Date:  2014-01-09       Impact factor: 5.639

2.  Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III.

Authors:  Heike Kölbel; Berthold P Hauffa; Stefan A Wudy; Anastasios Bouikidis; Adela Della Marina; Ulrike Schara
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

3.  Metabolic impairments in patients with myotonic dystrophy type 2.

Authors:  Milorad Vujnic; Stojan Peric; Zeljka Calic; Natasa Benovic; Tanja Nisic; Jovan Pesovic; Dusanka Savic-Pavicevic; Vidosava Rakocevic-Stojanovic
Journal:  Acta Myol       Date:  2018-12-01

Review 4.  Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1.

Authors:  Sylvia Nieuwenhuis; Kees Okkersen; Joanna Widomska; Paul Blom; Peter A C 't Hoen; Baziel van Engelen; Jeffrey C Glennon
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

Review 5.  Metabolic Alterations in Myotonic Dystrophy Type 1 and Their Correlation with Lipin.

Authors:  Tiago Mateus; Filipa Martins; Alexandra Nunes; Maria Teresa Herdeiro; Sandra Rebelo
Journal:  Int J Environ Res Public Health       Date:  2021-02-12       Impact factor: 3.390

6.  Myotonic Dystrophy Type 1 Complicated With Peripheral Arterial Occlusive Disease: A Case Report.

Authors:  Dong Hun Lee; Dong Sik Park; Dong Hyun Kim; Sang Hun Lee; Hee Mun Cho
Journal:  Ann Rehabil Med       Date:  2015-08-25

Review 7.  Clinical Care Recommendations for Cardiologists Treating Adults With Myotonic Dystrophy.

Authors:  Elizabeth M McNally; Douglas L Mann; Yigal Pinto; Deepak Bhakta; Gordon Tomaselli; Saman Nazarian; William J Groh; Takuhisa Tamura; Denis Duboc; Hideki Itoh; Leah Hellerstein; Pradeep P A Mammen
Journal:  J Am Heart Assoc       Date:  2020-02-06       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.